- Home
- TOI vs UNCY Comparison
TOI vs UNCY Comparison
Compare TOI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOI
- UNCY
- Stock Information
- Founded
- TOI 2007
- UNCY 2016
- Country
- TOI United States
- UNCY United States
- Employees
- TOI N/A
- UNCY N/A
- Industry
- TOI Medical/Nursing Services
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- TOI Health Care
- UNCY Health Care
- Exchange
- TOI Nasdaq
- UNCY Nasdaq
- Market Cap
- TOI 49.1M
- UNCY 58.7M
- IPO Year
- TOI N/A
- UNCY 2021
- Fundamental
- Price
- TOI $1.26
- UNCY $0.55
- Analyst Decision
- TOI
- UNCY Strong Buy
- Analyst Count
- TOI 0
- UNCY 3
- Target Price
- TOI N/A
- UNCY $6.50
- AVG Volume (30 Days)
- TOI 518.7K
- UNCY 925.3K
- Earning Date
- TOI 05-13-2025
- UNCY 05-12-2025
- Dividend Yield
- TOI N/A
- UNCY N/A
- EPS Growth
- TOI N/A
- UNCY N/A
- EPS
- TOI N/A
- UNCY N/A
- Revenue
- TOI $393,412,000.00
- UNCY N/A
- Revenue This Year
- TOI $23.95
- UNCY N/A
- Revenue Next Year
- TOI N/A
- UNCY $888.72
- P/E Ratio
- TOI N/A
- UNCY N/A
- Revenue Growth
- TOI 21.33
- UNCY N/A
- 52 Week Low
- TOI $0.13
- UNCY $0.20
- 52 Week High
- TOI $1.63
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- TOI 69.32
- UNCY 40.61
- Support Level
- TOI $0.97
- UNCY $0.60
- Resistance Level
- TOI $1.34
- UNCY $0.65
- Average True Range (ATR)
- TOI 0.18
- UNCY 0.05
- MACD
- TOI 0.04
- UNCY -0.01
- Stochastic Oscillator
- TOI 78.85
- UNCY 3.86
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.